Finanzen von Royalty Pharma PLC (RPRX)RPRXRoyalty Pharma PLC

Evaluating the bottom line, Royalty Pharma PLC maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 19.75%, while the net margin is 12.09%. These profitability ratios, combined with a Return on Equity (ROE) of 12.37%, provide a clear picture of how effectively RPRX converts its operational activities into shareholder value.

In the context of the broader market, RPRX competes directly with industry leaders such as BIIB and ALNY. With a market capitalization of $33.92B, it holds a leading position in the sector. When comparing efficiency, RPRX's gross margin of 100.00% stands against BIIB's 65.46% and ALNY's 76.88%. Such benchmarking helps identify whether Royalty Pharma PLC is trading at a premium or discount relative to its financial performance.

Royalty Pharma has shown robust financial performance with total revenues increasing from $593.64 million in Q4 2024 to $674.14 million in Q2 2026. The gross margin remains consistently high at 100%, and the net margin was 74.26% in Q1 2026, indicating strong profitability.